Amgen Company Profile (NASDAQ:AMGN)

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMGN
  • CUSIP: 03116210
  • Web:
  • Market Cap: $131.87 billion
  • Outstanding Shares: 735,399,000
Average Prices:
  • 50 Day Moving Avg: $169.47
  • 200 Day Moving Avg: $165.39
  • 52 Week Range: $133.64 - $184.21
  • Trailing P/E Ratio: 17.03
  • Foreward P/E Ratio: 14.03
  • P/E Growth: 3.36
Sales & Book Value:
  • Annual Revenue: $22.93 billion
  • Price / Sales: 5.75
  • Book Value: $41.62 per share
  • Price / Book: 4.31
  • Annual Dividend: $4.60
  • Dividend Yield: 2.6%
  • EBIDTA: $12.1 billion
  • Net Margins: 34.42%
  • Return on Equity: 29.37%
  • Return on Assets: 11.54%
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 4.41%
  • Quick Ratio: 4.14%
  • Average Volume: 3.39 million shs.
  • Beta: 1.36
  • Short Ratio: 2.57

Frequently Asked Questions for Amgen (NASDAQ:AMGN)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Tuesday, March 7th. Shareholders of record on Wednesday, May 17th will be given a dividend of $1.15 per share on Thursday, June 8th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date of this dividend is Monday, May 15th. View Amgen's Dividend History.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Wednesday, April, 26th. The company reported $3.15 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.00 by $0.15. The business had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.60 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The company's revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.90 EPS. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY17 earnings guidance on Wednesday, April, 26th. The company provided earnings per share (EPS) guidance of $12.00-12.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.34. The company issued revenue guidance of $22.3-23.1 billion, compared to the consensus revenue estimate of $23.02 billion.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

23 brokers have issued 1-year price targets for Amgen's stock. Their predictions range from $161.00 to $209.00. On average, they anticipate Amgen's share price to reach $185.63 in the next year. View Analyst Ratings for Amgen.

What are analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
  • 2. Cann analysts commented, "Positive data released yesterday for Amgen's cardiovascular drug, Repatha continues to support our growth expectations for Amgen. Amgen announced that four-year follow-up results from the OSLER-1 study were published in JAMA Cardiology. This is the longest PCSK9 inhibitor clinical trial to date. No new safety concerns identified and no neutralizing antibodies observed with cumulative exposure." (3/15/2017)
  • 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
  • 4. According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
  • David W. Meline, Executive Vice President, Chief Financial Officer
  • Sean E. Harper, Executive Vice President - Research and Development
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives
  • Esteban Santos, Executive Vice President, Operations
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
  • Lori A. Johnston, Senior Vice President
  • David A. Piacquad, Senior Vice President - Business Development

Who owns Amgen stock?

Amgen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.37%), NN Investment Partners Holdings N.V. (0.12%), US Bancorp DE (0.10%), Chevy Chase Trust Holdings Inc. (0.09%), National Pension Service (0.07%) and Gateway Investment Advisers LLC (0.06%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Fred Hassan, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bank of Montreal Can, NN Investment Partners Holdings N.V., Douglas Lane & Associates LLC, US Bancorp DE, Exxonmobil Investment Management Inc. TX, First American Trust FSB and Chemung Canal Trust Co.. Company insiders that have sold Amgen stock in the last year include Annette Louise Such and Cynthia M Patton. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was acquired by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Mn Services Vermogensbeheer B.V., Grimes & Company Inc., National Pension Service, Manning & Napier Advisors LLC, Swedbank, Aperio Group LLC and Sprott Inc.. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $179.32.

MarketBeat Community Rating for Amgen (NASDAQ AMGN)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  919 (Vote Outperform)
Underperform Votes:  537 (Vote Underperform)
Total Votes:  1,456
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $185.63 (3.52% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Jefferies Group LLCReiterated RatingBuy$195.00LowView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$177.00LowView Rating Details
7/14/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$189.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingOverweightLowView Rating Details
7/9/2017MizuhoReiterated RatingBuy$195.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/23/2017Deutsche Bank AGInitiated CoverageHold$172.00MediumView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
5/22/2017BMO Capital MarketsReiterated RatingBuy$200.00 -> $198.00LowView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
4/27/2017Cowen and CompanyReiterated RatingBuy$209.00LowView Rating Details
3/20/2017Goldman Sachs Group, Inc. (The)Lower Price TargetConviction-Buy$208.00 -> $202.00LowView Rating Details
3/15/2017CannReiterated RatingOutperform -> Positive$189.00MediumView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
2/11/2017ArgusSet Price TargetBuy$195.00N/AView Rating Details
1/31/2017Royal Bank Of CanadaSet Price TargetBuy$190.00N/AView Rating Details
2/1/2017Bank of America CorporationUpgradeNeutral -> Buy$156.68 -> $192.00N/AView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00N/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Amgen (NASDAQ:AMGN)
Earnings by Quarter for Amgen (NASDAQ:AMGN)
Earnings History by Quarter for Amgen (NASDAQ AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017$3.10N/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.35
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.05$3.12$3.09
Q3 20173$3.00$3.15$3.09
Q4 20173$2.98$3.13$3.07
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Most Recent Dividend:6/8/2017
Annual Dividend:$4.60
Dividend Yield:2.57%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:43.68% (Trailing 12 Months of Earnings)
36.92% (Based on This Year's Estimates)
35.99% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Dividend History by Quarter for Amgen (NASDAQ AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 78.80%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoFDA accepts Amgen's marketing application for migraine biologic erenumab, action date May 17, 2018 - July 20 at 5:16 PM logoAmgen Announces Webcast of 2017 Second Quarter Financial Results - July 20 at 5:10 PM logoFDA Accepts Biologics License Application For Aimovig™ (erenumab) - July 20 at 5:10 PM logoBiotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs - July 19 at 5:01 PM logoBiotech Stocks On Verge Of Next Major Move Up - July 19 at 5:01 PM logoLeerink Swann Comments on Amgen Inc.'s Q2 2017 Earnings (AMGN) - July 19 at 10:55 AM logoColorado biotech makes deal with industry giant - July 18 at 5:17 PM logoWhich Biotech Earnings Will Outperform? - July 18 at 5:17 PM logoAmgen Inc. (AMGN) to Post FY2018 Earnings of $12.66 Per Share, Leerink Swann Forecasts - July 18 at 1:18 PM logoAmgen Inc. (NASDAQ:AMGN) Scheduled to Post Earnings on Tuesday - July 18 at 8:16 AM logoAmgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA - July 18 at 2:16 AM logoAmgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA - July 18 at 2:16 AM logoAmgen FDA Letter Isn't A Surprise (Or A Concern), Says Jefferies - Barron's - July 17 at 9:14 PM logoAmgen Gets Romo FOMO - Seeking Alpha - July 17 at 4:11 PM logoAmgen's (NASDAQ:AMGN) Buy Rating Reaffirmed at Jefferies Group LLC - July 17 at 11:58 AM logoAmgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US - July 16 at 8:36 PM logoCredit Suisse Group Reaffirms Hold Rating for Amgen Inc. (AMGN) - July 15 at 1:40 PM logoNotable Friday Option Activity: REGN, DDD, AMGN - Nasdaq - July 14 at 5:35 PM logoAmgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label - July 14 at 5:35 PM logoAmgen Applies to Have Kyprolis' Label Updated - July 14 at 5:35 PM logoAmgen Inc. (AMGN) Earns Outperform Rating from Oppenheimer Holdings, Inc. - July 14 at 12:20 PM logoTrade of the Day: Amgen, Inc. (AMGN) Stock Is a Standout - July 14 at 7:51 AM logoAmgen's Myeloma Drug Improves Overall Survival in Phase III - Nasdaq - July 13 at 4:36 PM logoShort Sellers Hike Bets in Major Biotechs - 24/7 Wall St. - July 13 at 4:36 PM logoAmgen Receives FDA Approval For BLINCYTO - Seeking Alpha - July 13 at 4:36 PM logoShort Sellers Hike Bets in Major Biotechs - July 13 at 4:36 PM logoAmgen's Myeloma Drug Improves Overall Survival in Phase III - July 13 at 4:36 PM logoAmgen Inc. (AMGN) Forecasted to Earn Q3 2017 Earnings of $3.13 Per Share - July 13 at 9:56 AM logoFDA Grants Regular Approval to Amgen's (AMGN) Blinatumomab and Expands Indication - - July 12 at 9:18 PM logoAmgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label - July 12 at 4:16 PM logoBiotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal - July 12 at 4:16 PM logoAmgen's Leukemia Drug Gets Full FDA Approval - July 12 at 4:16 PM logoSecond Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma - July 12 at 4:16 PM logoAmgen Inc. (NASDAQ:AMGN) Expected to Announce Quarterly Sales of $5.68 Billion - July 12 at 9:14 AM logoAmgen Inc. Expected to Earn Q2 2017 Earnings of $3.11 Per Share (AMGN) - July 12 at 8:06 AM logoFDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children - July 11 at 10:07 PM logoAmgen And QB3@953 Announce Winners Of The Amgen Golden Ticket - July 11 at 5:04 PM logoHere's What's Behind Amgen, Inc.'s 10.2% Gain in June - July 11 at 1:47 AM logo$3.08 EPS Expected for Amgen Inc. (NASDAQ:AMGN) This Quarter - July 10 at 10:22 PM logoAmgen Inc. (AMGN) Earns Overweight Rating from Morgan Stanley - July 10 at 9:40 PM logoThe 10 largest pharmaceutical companies in the world - July 10 at 8:45 PM logoAmgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios - - July 10 at 3:44 PM logoThe Rise of Amgen Stock in 2Q17 - July 10 at 3:44 PM logoAmgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios - July 10 at 11:55 AM logoHere's What's Behind Amgen, Inc.'s 10.2% Gain in June - July 10 at 11:29 AM logoAmgen Inc. (AMGN) Given Buy Rating at Mizuho - July 9 at 7:19 AM logoAmgen Inc. (AMGN) Lifted to "Buy" at ValuEngine - July 9 at 12:40 AM logoImproving Health for This Pharma ETF - July 8 at 5:16 AM logoIs Amgen Making a Mistake? - July 8 at 5:16 AM logoMerck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies - July 7 at 3:15 AM



Amgen (AMGN) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff